Skip to main content
Top
Published in: Current Rheumatology Reports 1/2015

01-01-2015 | Scleroderma (J Varga, Section Editor)

Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis Pathogenesis

Authors: Sonsoles Piera-Velazquez, Sergio A. Jimenez

Published in: Current Rheumatology Reports | Issue 1/2015

Login to get access

Abstract

Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and numerous internal organs and a severe fibroproliferative vasculopathy resulting frequently in severe disability and high mortality. Although the etiology of SSc is unknown and the detailed mechanisms responsible for the fibrotic process have not been fully elucidated, one important observation from a large US population study was the demonstration of a late onset of SSc with a peak incidence between 45 and 54 years of age in African-American females and between 65 and 74 years of age in white females. Although it is not appropriate to consider SSc as a disease of aging, the possibility that senescence changes in the cellular elements involved in its pathogenesis may play a role has not been thoroughly examined. The process of cellular senescence is extremely complex, and the mechanisms, molecular events, and signaling pathways involved have not been fully elucidated; however, there is strong evidence to support the concept that oxidative stress caused by the excessive generation of reactive oxygen species may be one important mechanism involved. On the other hand, numerous studies have implicated oxidative stress in SSc pathogenesis, thus, suggesting a plausible mechanism in which excessive oxidative stress induces cellular senescence and that the molecular events associated with this complex process play an important role in the fibrotic and fibroproliferative vasculopathy characteristic of SSc. Here, recent studies examining the role of cellular senescence and of oxidative stress in SSc pathogenesis will be reviewed.
Literature
1.
go back to reference Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.PubMed Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.PubMed
2.
go back to reference Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65:1953–62.PubMed Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65:1953–62.PubMed
3.
go back to reference Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51:1017–26. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51:1017–26.
4.
go back to reference Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. J Mol Med (Berl). 2014;92:913–24. Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. J Mol Med (Berl). 2014;92:913–24.
5.
go back to reference Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509–37.PubMed Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509–37.PubMed
6.
go back to reference Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011;25:42–54. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011;25:42–54.
7.
8.
go back to reference Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246–55.PubMed Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246–55.PubMed
9.
go back to reference Hayflick L, Moorehead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.PubMed Hayflick L, Moorehead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.PubMed
10.
go back to reference Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614–36.PubMed Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614–36.PubMed
12.
13.
go back to reference Muñoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15:482–96.PubMed Muñoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15:482–96.PubMed
14.
go back to reference Sikora E, Arendt T, Bennett M, Narita M. Impact of cellular senescence signature on ageing research. Ageing Res Rev. 2011;10:146–52.PubMed Sikora E, Arendt T, Bennett M, Narita M. Impact of cellular senescence signature on ageing research. Ageing Res Rev. 2011;10:146–52.PubMed
15.
go back to reference Erol A. Deciphering the intricate regulatory mechanisms for the cellular choice between cell repair, apoptosis or senescence in response to damaging signals. Cell Signal. 2011;23:1076–81.PubMed Erol A. Deciphering the intricate regulatory mechanisms for the cellular choice between cell repair, apoptosis or senescence in response to damaging signals. Cell Signal. 2011;23:1076–81.PubMed
16.
go back to reference Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37:961–76.PubMed Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37:961–76.PubMed
17.••
go back to reference Campisi J, Anderson JK, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol. 2011;21:354–9. Review of the studies that lead to the identification of the “Senescence Associated Secretory Phenotype”.PubMedCentralPubMed Campisi J, Anderson JK, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol. 2011;21:354–9. Review of the studies that lead to the identification of the “Senescence Associated Secretory Phenotype”.PubMedCentralPubMed
18.
go back to reference Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966–72.PubMedCentralPubMed Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966–72.PubMedCentralPubMed
19.
go back to reference Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med. 2010;16:238–46.PubMedCentralPubMed Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med. 2010;16:238–46.PubMedCentralPubMed
20.
go back to reference Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.PubMedCentralPubMed Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.PubMedCentralPubMed
21.
go back to reference Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal. 2012;24:835–45.PubMed Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal. 2012;24:835–45.PubMed
22.••
go back to reference Muñoz-Espin D, Canamero M, Maraver A, Gomez-Lopez G, Contreras J, Murillo-Cuesta S, et al. Programmed cell senescence during mammalian embryonic development. Cell. 2013;155:1104–18.PubMed Muñoz-Espin D, Canamero M, Maraver A, Gomez-Lopez G, Contreras J, Murillo-Cuesta S, et al. Programmed cell senescence during mammalian embryonic development. Cell. 2013;155:1104–18.PubMed
23.••
go back to reference Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell. 2013;155:1119–30. Refs. 22 and 23 describe elegant studies identifying the role of cellular senescence during embryonic growth and development.PubMed Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell. 2013;155:1119–30. Refs. 22 and 23 describe elegant studies identifying the role of cellular senescence during embryonic growth and development.PubMed
24.
go back to reference Chen JH, Hales CN, Ozanne SE. DNA damage, cellular senescence and organismal ageing: casual or correlative? Nucleic Acids Res. 2007;35:7417–28.PubMedCentralPubMed Chen JH, Hales CN, Ozanne SE. DNA damage, cellular senescence and organismal ageing: casual or correlative? Nucleic Acids Res. 2007;35:7417–28.PubMedCentralPubMed
25.
go back to reference Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130:223–33.PubMed Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130:223–33.PubMed
26.
go back to reference Gorgoulis VG, Halazonetis TD. Oncogene induced senescence: the bright and dark side of the response. Curr Opin Cell Biol. 2010;22:816–27.PubMed Gorgoulis VG, Halazonetis TD. Oncogene induced senescence: the bright and dark side of the response. Curr Opin Cell Biol. 2010;22:816–27.PubMed
28.
go back to reference Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;354:458–60. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;354:458–60.
29.
go back to reference Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci U S A. 1995;92:4337–41.PubMedCentralPubMed Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci U S A. 1995;92:4337–41.PubMedCentralPubMed
30.
go back to reference Chen QM. Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann N Y Acad Sci. 2000;908:111–25.PubMed Chen QM. Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann N Y Acad Sci. 2000;908:111–25.PubMed
31.
go back to reference Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol. 2003;5:741–7.PubMed Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol. 2003;5:741–7.PubMed
32.
go back to reference Passos JF, Simillion C, Hallinan J, Wipat A, von Zglinicki T. Cellular senescence: unraveling complexity. Age (Dordrecht). 2009;31:353–63. Passos JF, Simillion C, Hallinan J, Wipat A, von Zglinicki T. Cellular senescence: unraveling complexity. Age (Dordrecht). 2009;31:353–63.
33.
go back to reference Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal. 2009;11:59–98.PubMed Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal. 2009;11:59–98.PubMed
34.
go back to reference Passos JF, Nelson G, Wang C, Richter T, Simillion C, Proctor CJ, et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol. 2010;6:347.PubMedCentralPubMed Passos JF, Nelson G, Wang C, Richter T, Simillion C, Proctor CJ, et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol. 2010;6:347.PubMedCentralPubMed
35.
go back to reference Kim TK, Lee JS, Jung JE, Oh SY, Kwak S, Jin X, et al. Interferon regulatory factor 3 activates p53-dependent cell growth inhibition. Cancer Lett. 2006;242:215–21.PubMed Kim TK, Lee JS, Jung JE, Oh SY, Kwak S, Jin X, et al. Interferon regulatory factor 3 activates p53-dependent cell growth inhibition. Cancer Lett. 2006;242:215–21.PubMed
36.
go back to reference Song LL, Alimirah F, Panchanathan R, Xin H, Choubey D. Expression of an IFN-inducible cellular senescence gene, IFI16, is up-regulated by p53. Mol Cancer Res. 2008;6:1732–41.PubMed Song LL, Alimirah F, Panchanathan R, Xin H, Choubey D. Expression of an IFN-inducible cellular senescence gene, IFI16, is up-regulated by p53. Mol Cancer Res. 2008;6:1732–41.PubMed
37.
go back to reference Duan X, Ponomareva L, Veeranki S, Panchanathan R, Dickerson E, Choubey D. Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cystosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res. 2011;9:589–602.PubMedCentralPubMed Duan X, Ponomareva L, Veeranki S, Panchanathan R, Dickerson E, Choubey D. Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cystosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res. 2011;9:589–602.PubMedCentralPubMed
38.••
go back to reference Dumit VI, Kuttner V, Kappler J, Piera-Velazquez S, Jimenez SA, Bruckner-Tuderman L, et al. Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2014;134:2321–30. Novel study demonstrating the occurrence of cellular senescence-associated changes in Systemic Sclerosis dermal fibroblast cell lines employing proteomics.PubMed Dumit VI, Kuttner V, Kappler J, Piera-Velazquez S, Jimenez SA, Bruckner-Tuderman L, et al. Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2014;134:2321–30. Novel study demonstrating the occurrence of cellular senescence-associated changes in Systemic Sclerosis dermal fibroblast cell lines employing proteomics.PubMed
39.
go back to reference Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007;56:1994–2004.PubMed Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007;56:1994–2004.PubMed
40.
go back to reference Goronzy J, Fujii H, Weyand CM. Telomeres, immune aging, and autoimmunity. Exp Gerontol. 2006;41:246–51.PubMed Goronzy J, Fujii H, Weyand CM. Telomeres, immune aging, and autoimmunity. Exp Gerontol. 2006;41:246–51.PubMed
41.
go back to reference Debbi AZ, Radstake TRDJ, Broen JCA. Accelerated telomere shortening in rheumatic diseases: cause or consequence? Expert Rev Clin Immunol. 2013;9:1193–204. Debbi AZ, Radstake TRDJ, Broen JCA. Accelerated telomere shortening in rheumatic diseases: cause or consequence? Expert Rev Clin Immunol. 2013;9:1193–204.
42.
go back to reference Arlett CM, Black CM, Briggs DC, Stevens CO, Welsh KI. Telomere reduction in scleroderma patients: a possible cause for chromosomal instability. Br J Rheumatol. 1996;35:732–7. Arlett CM, Black CM, Briggs DC, Stevens CO, Welsh KI. Telomere reduction in scleroderma patients: a possible cause for chromosomal instability. Br J Rheumatol. 1996;35:732–7.
43.
go back to reference Ohtsuka T. Life span of skin fibroblasts in patients with systemic sclerosis. Dermatology. 1998;196:204–7.PubMed Ohtsuka T. Life span of skin fibroblasts in patients with systemic sclerosis. Dermatology. 1998;196:204–7.PubMed
44.
go back to reference MacIntyre A, Brouilette SW, Lamb K, Radhakrishnan K, McGlynn L, Chee MM, et al. Association of increased telomere lengths in limited scleroderma, with a lack of age-related telomere erosion. Ann Rheum Dis. 2008;67:1780–2.PubMed MacIntyre A, Brouilette SW, Lamb K, Radhakrishnan K, McGlynn L, Chee MM, et al. Association of increased telomere lengths in limited scleroderma, with a lack of age-related telomere erosion. Ann Rheum Dis. 2008;67:1780–2.PubMed
45.
go back to reference Tarhan F, Vural F, Kosova B, Aksu K, Cogulu O, Keser G. Telomerase activity in connective tissue diseases: elevated in rheumatoid arthritis, but markedly decreased in systemic sclerosis. Rheumatol Int. 2008;28:579–83.PubMed Tarhan F, Vural F, Kosova B, Aksu K, Cogulu O, Keser G. Telomerase activity in connective tissue diseases: elevated in rheumatoid arthritis, but markedly decreased in systemic sclerosis. Rheumatol Int. 2008;28:579–83.PubMed
46.
go back to reference Thannickal VJ. Mechanistic links between aging and lung fibrosis. Biogerontology. 2013;14:609–15.PubMed Thannickal VJ. Mechanistic links between aging and lung fibrosis. Biogerontology. 2013;14:609–15.PubMed
47.
go back to reference Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res. 2013;162:156–73.PubMed Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res. 2013;162:156–73.PubMed
48.
go back to reference Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med. 2013;64:265–76.PubMed Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med. 2013;64:265–76.PubMed
49.
go back to reference Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356:1317–26.PubMed Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356:1317–26.PubMed
50.
go back to reference Diazdeleon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5:e10680. doi:10.1371/journal.pone.0010680. Diazdeleon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5:e10680. doi:10.​1371/​journal.​pone.​0010680.
51.
go back to reference Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008;58:2854–65.PubMedCentralPubMed Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008;58:2854–65.PubMedCentralPubMed
52.
go back to reference Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2008;20:713–9.PubMedCentralPubMed Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2008;20:713–9.PubMedCentralPubMed
53.
go back to reference Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203:2895–906.PubMedCentralPubMed Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203:2895–906.PubMedCentralPubMed
54.
go back to reference Tourkina E, Richard M, Gööz P, Bonner M, Pannu J, Harley R, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008;294:L843–61.PubMed Tourkina E, Richard M, Gööz P, Bonner M, Pannu J, Harley R, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008;294:L843–61.PubMed
55.••
go back to reference Gvaramia D, Blaauboer ME, Hanemaaijer R, Everts V. Role of caveolin-1 in fibrotic diseases. Matrix Biol. 2013;32:307–15. Comprehensive review of the extensive published evidence demonstrating the crucial role of caveolin-1 in the pathogenesis of various fibrotic diseases including Systemic Sclerosis.PubMed Gvaramia D, Blaauboer ME, Hanemaaijer R, Everts V. Role of caveolin-1 in fibrotic diseases. Matrix Biol. 2013;32:307–15. Comprehensive review of the extensive published evidence demonstrating the crucial role of caveolin-1 in the pathogenesis of various fibrotic diseases including Systemic Sclerosis.PubMed
56.
go back to reference Volonte D, Zhang K, Lisanti MP, Galbiati F. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell. 2002;13:2502–17.PubMedCentralPubMed Volonte D, Zhang K, Lisanti MP, Galbiati F. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell. 2002;13:2502–17.PubMedCentralPubMed
57.
go back to reference Shivshankar P, Brampton C, Miyasato S, Kasper M, Thannickal VJ, Le Saux CJ. Caveolin-1 deficiency protects from pulmonary fibrosis by modulating epithelial cell senescence in mice. Am J Respir Cell Mol Biol. 2012;47:28–36.PubMedCentralPubMed Shivshankar P, Brampton C, Miyasato S, Kasper M, Thannickal VJ, Le Saux CJ. Caveolin-1 deficiency protects from pulmonary fibrosis by modulating epithelial cell senescence in mice. Am J Respir Cell Mol Biol. 2012;47:28–36.PubMedCentralPubMed
58.
go back to reference Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol. 2010;176:2626–37.PubMedCentralPubMed Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol. 2010;176:2626–37.PubMedCentralPubMed
59.
go back to reference Parapuram SK, Shi-wen X, Elliott C, Welch ID, Jones H, Baron M, et al. Loss of PTEN expression by dermal fibroblasts causes fibrosis. J Invest Dermatol. 2011;131:1996–2003.PubMed Parapuram SK, Shi-wen X, Elliott C, Welch ID, Jones H, Baron M, et al. Loss of PTEN expression by dermal fibroblasts causes fibrosis. J Invest Dermatol. 2011;131:1996–2003.PubMed
60.
go back to reference Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol. 1993;28:78–85.PubMed Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol. 1993;28:78–85.PubMed
61.
go back to reference Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Semin Immunopathol. 2008;30:329–37.PubMed Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Semin Immunopathol. 2008;30:329–37.PubMed
62.
go back to reference Piera-Velazquez S, Jimenez SA. Role of oxidative stress and reactive oxygen radicals in the pathogenesis of systemic sclerosis. In: MJ Alcaraz, editors. Studies on arthritis and joint disorders, oxidative stress in applied basic research and clinical practice. doi:10.1007/978-1-4614-6166-1_10.pp.183-197. Piera-Velazquez S, Jimenez SA. Role of oxidative stress and reactive oxygen radicals in the pathogenesis of systemic sclerosis. In: MJ Alcaraz, editors. Studies on arthritis and joint disorders, oxidative stress in applied basic research and clinical practice. doi:10.​1007/​978-1-4614-6166-1_​10.​pp.​183-197.
63.
go back to reference Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012;6:87–95.PubMedCentralPubMed Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012;6:87–95.PubMedCentralPubMed
64.••
go back to reference Ogawa F, Shimizu K, Muroi E, Hara T, Sato S. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol. 2011;30:921–5. This study measured the total antioxidant power in serum from SSc patients and found that approximately one-quarter of these patients had elevated levels although there were no differences between patients with the diffuse or limited SSc subsets.PubMed Ogawa F, Shimizu K, Muroi E, Hara T, Sato S. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol. 2011;30:921–5. This study measured the total antioxidant power in serum from SSc patients and found that approximately one-quarter of these patients had elevated levels although there were no differences between patients with the diffuse or limited SSc subsets.PubMed
65.••
go back to reference Savas E, Aksoy N, Pehlivan Y, Sayiner ZA, Oztürk ZA, Tabur S, et al. Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien Klin Wochenschr. 2014;126:341–6. This interesting study demonstrated that the “total oxidant status” and the “oxidative stress index” were higher in Systemic Sclerosis patients than in healthy controls whereas there were no differences in “total antioxidant status”.PubMed Savas E, Aksoy N, Pehlivan Y, Sayiner ZA, Oztürk ZA, Tabur S, et al. Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien Klin Wochenschr. 2014;126:341–6. This interesting study demonstrated that the “total oxidant status” and the “oxidative stress index” were higher in Systemic Sclerosis patients than in healthy controls whereas there were no differences in “total antioxidant status”.PubMed
66.
go back to reference Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol. 1999;112:78–84.PubMed Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol. 1999;112:78–84.PubMed
67.
go back to reference Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med. 2004;116:595–600.PubMed Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med. 2004;116:595–600.PubMed
68.
go back to reference Servettaz A, Guilpain P, Goulvestre C, Chereau C, Hercend C, Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis. 2007;66:1202–9.PubMedCentralPubMed Servettaz A, Guilpain P, Goulvestre C, Chereau C, Hercend C, Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis. 2007;66:1202–9.PubMedCentralPubMed
69.
go back to reference Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini S, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44:2653–64.PubMed Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini S, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44:2653–64.PubMed
70.
go back to reference Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative damage in systemic sclerosis. J Rheumatol. 2010;37:2540–7.PubMed Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative damage in systemic sclerosis. J Rheumatol. 2010;37:2540–7.PubMed
71.
go back to reference Stein CM, Tanner SB, Awad JA, Roberts II LJ, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 1996;39:1146–50.PubMed Stein CM, Tanner SB, Awad JA, Roberts II LJ, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 1996;39:1146–50.PubMed
72.
go back to reference Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford). 2006;45:815–8. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford). 2006;45:815–8.
73.
go back to reference Cracowski JL, Marpeau C, Carpentier PH, Imbert B, Hunt M, Stanke-Labesque F, et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum. 2001;44:1143–8.PubMed Cracowski JL, Marpeau C, Carpentier PH, Imbert B, Hunt M, Stanke-Labesque F, et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum. 2001;44:1143–8.PubMed
74.
go back to reference Volpe A, Biasi D, Caramaschi P, Mantovani W, Bambara LM, Canestrini S, et al. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford). 2006;45:314–20. Volpe A, Biasi D, Caramaschi P, Mantovani W, Bambara LM, Canestrini S, et al. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford). 2006;45:314–20.
75.
go back to reference Tufvesson E, Bozovic G, Hesselstrand R, Bjermer L, Scheja A, Wuttge DM. Increased cysteinyl-leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients. Rheumatology (Oxford). 2010;49:2322–6. Tufvesson E, Bozovic G, Hesselstrand R, Bjermer L, Scheja A, Wuttge DM. Increased cysteinyl-leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients. Rheumatology (Oxford). 2010;49:2322–6.
76.
go back to reference Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev. 2000;32:377–85.PubMed Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev. 2000;32:377–85.PubMed
77.
go back to reference Shimizu K, Ogawa F, Akiyama Y, Muroi E, Yoshizaki A, Iwata Y, et al. Increased serum levels of N(epsilon)-(hexanoyl)lysine, a new marker of oxidative stress, in systemic sclerosis. J Rheumatol. 2008;35:2214–9.PubMed Shimizu K, Ogawa F, Akiyama Y, Muroi E, Yoshizaki A, Iwata Y, et al. Increased serum levels of N(epsilon)-(hexanoyl)lysine, a new marker of oxidative stress, in systemic sclerosis. J Rheumatol. 2008;35:2214–9.PubMed
78.
go back to reference Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K, et al. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol. 2008;26:659–62.PubMed Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K, et al. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol. 2008;26:659–62.PubMed
79.
go back to reference Boin F, Erre GL, Posadino AM, Cossu A, Giordo R, Spinetti G, et al. Oxidative stress-dependent activation of collagen synthesis is induced in human pulmonary smooth muscle cells by sera from patients with scleroderma-associated pulmonary hypertension. Orphanet J Rare Dis. 2014;9:123.PubMedCentralPubMed Boin F, Erre GL, Posadino AM, Cossu A, Giordo R, Spinetti G, et al. Oxidative stress-dependent activation of collagen synthesis is induced in human pulmonary smooth muscle cells by sera from patients with scleroderma-associated pulmonary hypertension. Orphanet J Rare Dis. 2014;9:123.PubMedCentralPubMed
80.
go back to reference Holmström KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol. 2014;15:411–21.PubMed Holmström KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol. 2014;15:411–21.PubMed
81.
go back to reference Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24:R453–62.PubMed Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24:R453–62.PubMed
83.••
go back to reference Svegliati S, Marrone G, Pezone A, Spadoni T, Grieco A, Moroncini G, et al. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal. 2014;7(341):ra84. doi:10.1126/scisignal.2004592. Extensive study that ties together ROS-mediated oxidative stress, DNA damage and activation of the Wnt fibrotic pathway caused by ROS-induced loss of the anti-Wnt protein, Wnt inhibitory factor 1 (WIF-1).PubMed Svegliati S, Marrone G, Pezone A, Spadoni T, Grieco A, Moroncini G, et al. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal. 2014;7(341):ra84. doi:10.​1126/​scisignal.​2004592. Extensive study that ties together ROS-mediated oxidative stress, DNA damage and activation of the Wnt fibrotic pathway caused by ROS-induced loss of the anti-Wnt protein, Wnt inhibitory factor 1 (WIF-1).PubMed
84.••
go back to reference Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford). 2010;49:2024–36. Highly provocative study demonstrating modulation of the profibrotic phenotype of Systemic Sclerosis dermal fibroblasts by the antioxidant epigallocatechin-3-gallate. Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford). 2010;49:2024–36. Highly provocative study demonstrating modulation of the profibrotic phenotype of Systemic Sclerosis dermal fibroblasts by the antioxidant epigallocatechin-3-gallate.
85.••
go back to reference Tsou PS, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, et al. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum. 2012;64:1978–89. Pioneering study exploring the role of PTP1B in the regulation of the fibrotic process in SSc demonstrating that PTP1B activity was substantially reduced in SSc dermal fibroblasts as a result of increased ROS-induced cysteine residue oxidation in the protein.PubMedCentralPubMed Tsou PS, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, et al. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum. 2012;64:1978–89. Pioneering study exploring the role of PTP1B in the regulation of the fibrotic process in SSc demonstrating that PTP1B activity was substantially reduced in SSc dermal fibroblasts as a result of increased ROS-induced cysteine residue oxidation in the protein.PubMedCentralPubMed
86.
go back to reference Kawahara T, Quinn MT, Lambeth JD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. BMC Evol Biol. 2007;7:109.PubMedCentralPubMed Kawahara T, Quinn MT, Lambeth JD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. BMC Evol Biol. 2007;7:109.PubMedCentralPubMed
87.
go back to reference Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008;275:3249–77.PubMed Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008;275:3249–77.PubMed
88.
go back to reference Lambeth JD, Neish AS. Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu Rev Pathol. 2014;9:119–45.PubMed Lambeth JD, Neish AS. Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu Rev Pathol. 2014;9:119–45.PubMed
89.
go back to reference Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.PubMed Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.PubMed
90.
go back to reference Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res. 2006;71:289–99.PubMed Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res. 2006;71:289–99.PubMed
91.
go back to reference Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97:900–7.PubMed Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97:900–7.PubMed
92.
go back to reference Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, et al. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Moll Physiol. 2006;290:L661–73. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, et al. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Moll Physiol. 2006;290:L661–73.
93.
go back to reference Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15:1077–81.PubMedCentralPubMed Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15:1077–81.PubMedCentralPubMed
94.
go back to reference Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol. 2007;27:2319–24.PubMed Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol. 2007;27:2319–24.PubMed
95.
go back to reference An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res. 2007;75:702–9.PubMed An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res. 2007;75:702–9.PubMed
96.
go back to reference Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun. 2000;269:713–7.PubMed Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun. 2000;269:713–7.PubMed
97.
go back to reference Manickam N, Patel M, Griendling KK, Gorin Y, Barnes JL. RhoA/Rho kinase mediate TGF-β1-induced kidney myofibroblast activation through Poldip2/NOX4-derived reactive oxygen species. Am J Physiol Renal Physiol. 2014;307:F159–71.PubMed Manickam N, Patel M, Griendling KK, Gorin Y, Barnes JL. RhoA/Rho kinase mediate TGF-β1-induced kidney myofibroblast activation through Poldip2/NOX4-derived reactive oxygen species. Am J Physiol Renal Physiol. 2014;307:F159–71.PubMed
98.
go back to reference Bondi CD, Manickham N, Lee DY, Block K, Gorin Y, Abboud HE, et al. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol. 2010;21:93–102.PubMedCentralPubMed Bondi CD, Manickham N, Lee DY, Block K, Gorin Y, Abboud HE, et al. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol. 2010;21:93–102.PubMedCentralPubMed
99.
go back to reference Barnes JL, Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011;79:944–56.PubMedCentralPubMed Barnes JL, Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011;79:944–56.PubMedCentralPubMed
100.
go back to reference Alili L, Sack M, Puschmann K, Brenneisen P. Fibroblast-to-myofibroblast switch is mediated by NAD(P)H oxidase generated reactive oxygen species. Biosci Rep. 2013. Alili L, Sack M, Puschmann K, Brenneisen P. Fibroblast-to-myofibroblast switch is mediated by NAD(P)H oxidase generated reactive oxygen species. Biosci Rep. 2013.
101.
go back to reference Siani A, Tirelli N. Myofibroblast differentiation: main features, biomedical relevance, and the role of reactive oxygen species. Antioxid Redox Signal. 2014;21:768–85.PubMed Siani A, Tirelli N. Myofibroblast differentiation: main features, biomedical relevance, and the role of reactive oxygen species. Antioxid Redox Signal. 2014;21:768–85.PubMed
102.
go back to reference Shen WL, Gao PJ, Che ZQ, Ji KD, Yin M, Yan C, et al. NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotype differentiation. Biochem Biophys Res Commun. 2006;339:337–43.PubMed Shen WL, Gao PJ, Che ZQ, Ji KD, Yin M, Yan C, et al. NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotype differentiation. Biochem Biophys Res Commun. 2006;339:337–43.PubMed
103.
go back to reference Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta-1-induced fibroblast differentiation into myofibroblasts. Thorax. 2010;65:733–8.PubMedCentralPubMed Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta-1-induced fibroblast differentiation into myofibroblasts. Thorax. 2010;65:733–8.PubMedCentralPubMed
104.
go back to reference Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA. Role of NADPH oxidase in liver fibrosis. Antioxid Redox Signal. 2014;20:2854–72.PubMed Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA. Role of NADPH oxidase in liver fibrosis. Antioxid Redox Signal. 2014;20:2854–72.PubMed
105.
go back to reference Babalola O, Mamalis A, Lev-Tov H, Jagdeo J. NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents. Arch Dermatol Res. 2014;306:313–30.PubMed Babalola O, Mamalis A, Lev-Tov H, Jagdeo J. NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents. Arch Dermatol Res. 2014;306:313–30.PubMed
106.
go back to reference Böhm M, Dosoki H, Kerkhoff C. Is Nox4 a key regulator of the activated state of fibroblasts in systemic sclerosis? Exp Dermatol. 2014. doi:10.1111/exd.12497. Böhm M, Dosoki H, Kerkhoff C. Is Nox4 a key regulator of the activated state of fibroblasts in systemic sclerosis? Exp Dermatol. 2014. doi:10.​1111/​exd.​12497.
107.••
go back to reference Montorfano I, Becerra A, Cerro R, Echeverria C, Saez E, Morales MG, et al. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-β1 and TGF-β2-dependent pathway. Lab Invest. 2014. doi:10.1038/labinvest.2014.100. Important study showing that oxidative stress was capable of inducing a phenotypic change of endothelial cells into myofibroblasts through a TGF-β dependent mechanism.PubMed Montorfano I, Becerra A, Cerro R, Echeverria C, Saez E, Morales MG, et al. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-β1 and TGF-β2-dependent pathway. Lab Invest. 2014. doi:10.​1038/​labinvest.​2014.​100. Important study showing that oxidative stress was capable of inducing a phenotypic change of endothelial cells into myofibroblasts through a TGF-β dependent mechanism.PubMed
108.
go back to reference Serrander L, Cartier L, Bedard K, Bandi B, Lardy B, Plastre O. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J. 2007;406:105–14.PubMedCentralPubMed Serrander L, Cartier L, Bedard K, Bandi B, Lardy B, Plastre O. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J. 2007;406:105–14.PubMedCentralPubMed
109.
go back to reference Jiang F, Liu GS, Dusting GJ, Chan EC. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox Biol. 2014;2:267–72.PubMedCentralPubMed Jiang F, Liu GS, Dusting GJ, Chan EC. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox Biol. 2014;2:267–72.PubMedCentralPubMed
110.
go back to reference Bai G, Hock TD, Logsdon N, Zhou Y, Thannickal VJ. A far-upstream AP-1/Smad binding box regulates human NOX4 promoter activation by transforming growth factor-β. Gene. 2014;540:62–7.PubMed Bai G, Hock TD, Logsdon N, Zhou Y, Thannickal VJ. A far-upstream AP-1/Smad binding box regulates human NOX4 promoter activation by transforming growth factor-β. Gene. 2014;540:62–7.PubMed
111.••
go back to reference Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, et al. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res. 2009;105:249–59. This paper describes the exciting new findings that polymerase delta interacting protein 2 (Poldip2) interacts with NOX4 and is capable of increasing NOX4 activity by three-fold.PubMedCentralPubMed Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, et al. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res. 2009;105:249–59. This paper describes the exciting new findings that polymerase delta interacting protein 2 (Poldip2) interacts with NOX4 and is capable of increasing NOX4 activity by three-fold.PubMedCentralPubMed
112.
go back to reference Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. 2000;155:1–15.PubMed Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. 2000;155:1–15.PubMed
113.
go back to reference Erre GL, De Muro P, Dellaca P, et al. Iloprost therapy acutely decreases oxidative stress in patients affected by systemic sclerosis. Clin Exp Rheumatol. 2008;26:1095–8.PubMed Erre GL, De Muro P, Dellaca P, et al. Iloprost therapy acutely decreases oxidative stress in patients affected by systemic sclerosis. Clin Exp Rheumatol. 2008;26:1095–8.PubMed
114.
go back to reference Volpe A, Biasi D, Caramaschi P, et al. Iloprost infusion does not reduce oxidative stress in systemic sclerosis. Rheumatol Int. 2008;28:335–7.PubMed Volpe A, Biasi D, Caramaschi P, et al. Iloprost infusion does not reduce oxidative stress in systemic sclerosis. Rheumatol Int. 2008;28:335–7.PubMed
115.
go back to reference Erre GL, Passiu G. Antioxidant effect of iloprost: current knowledge and therapeutic implications for systemic sclerosis. Reumatismo. 2009;61:90–7.PubMed Erre GL, Passiu G. Antioxidant effect of iloprost: current knowledge and therapeutic implications for systemic sclerosis. Reumatismo. 2009;61:90–7.PubMed
116.
go back to reference Yoshizaki A, Yanaba K, Ogawa A, et al. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum. 2011;63:3086–97.PubMed Yoshizaki A, Yanaba K, Ogawa A, et al. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum. 2011;63:3086–97.PubMed
117.
go back to reference Marut WK, Kavian N, Servettaz A, et al. The organotelluride catalyst (PHTE)NQ prevents HOCl-induced systemic sclerosis in mouse. J Invest Dermatol. 2012;132:1125–32.PubMed Marut WK, Kavian N, Servettaz A, et al. The organotelluride catalyst (PHTE)NQ prevents HOCl-induced systemic sclerosis in mouse. J Invest Dermatol. 2012;132:1125–32.PubMed
118.
go back to reference Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol. 2001;28:2257–62.PubMed Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol. 2001;28:2257–62.PubMed
119.
go back to reference Cracowski JL, Girolet S, Imbert B, et al. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med. 2005;38:98–103.PubMed Cracowski JL, Girolet S, Imbert B, et al. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med. 2005;38:98–103.PubMed
120.
go back to reference Rosato E, Rossi C, Molinaro I, Giovannetti A, Pisarri S, Salsano F. Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. Int J Immunopathol Pharmacol. 2011;24:727–33.PubMed Rosato E, Rossi C, Molinaro I, Giovannetti A, Pisarri S, Salsano F. Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. Int J Immunopathol Pharmacol. 2011;24:727–33.PubMed
121.
go back to reference Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A. Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther. 2005;7:R93–R100.PubMedCentralPubMed Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A. Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther. 2005;7:R93–R100.PubMedCentralPubMed
122.
go back to reference Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979;38:356–61.PubMedCentralPubMed Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979;38:356–61.PubMedCentralPubMed
123.••
go back to reference Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic fibrosis. J Med Chem. 2010;53:7715–30.PubMed Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic fibrosis. J Med Chem. 2010;53:7715–30.PubMed
124.••
go back to reference Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, et al. Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine,-pyrazine and -oxazine dione derivatives as a novel dual Nox4/Nox1 inhibitors. Bioorg Med Chem. 2011;19:6989–99. References 123 and 124 describe the design and synthesis of a novel class of potent and highly selective NOX4 small molecule inhibitors.PubMed Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, et al. Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine,-pyrazine and -oxazine dione derivatives as a novel dual Nox4/Nox1 inhibitors. Bioorg Med Chem. 2011;19:6989–99. References 123 and 124 describe the design and synthesis of a novel class of potent and highly selective NOX4 small molecule inhibitors.PubMed
125.••
go back to reference El-Benna J, Dang PM, Perianin A. Towards specific NADPH oxidase inhibition by small synthetic peptides. Cell Mol Life Sci. 2012;69:2307–14. Description of novel and specific small synthetic peptides targeting NOX enzymes.PubMed El-Benna J, Dang PM, Perianin A. Towards specific NADPH oxidase inhibition by small synthetic peptides. Cell Mol Life Sci. 2012;69:2307–14. Description of novel and specific small synthetic peptides targeting NOX enzymes.PubMed
126.
go back to reference Altenhöfer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2014. Altenhöfer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2014.
127.
go back to reference Altenhöfer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci. 2012;69:2327–43.PubMedCentralPubMed Altenhöfer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci. 2012;69:2327–43.PubMedCentralPubMed
128.
go back to reference Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, Thapa. NADPH oxidase inhibitors: a patent review. Expert Opin Ther Patent. 2011;21:1147–58. Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, Thapa. NADPH oxidase inhibitors: a patent review. Expert Opin Ther Patent. 2011;21:1147–58.
129.
go back to reference Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology. 2012;56:2316–27.PubMedCentralPubMed Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology. 2012;56:2316–27.PubMedCentralPubMed
130.••
go back to reference Jarman ER, Khambata VS, Cope C, Jones P, Roger J, Ye LY, et al. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model. Am J Respir Cell Mol Biol. 2014;50:158–69. Highly relevant study demonstrating that inhibition of NOX4 activity employing a small molecule antagonist decreased TGF-β1-induced upregulation of profibrotic genes in normal human lung fibroblasts in vitro and attenuated established lung fibrosis in vivo in bleomycin-induced animal model of pulmonary fibrosis.PubMed Jarman ER, Khambata VS, Cope C, Jones P, Roger J, Ye LY, et al. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model. Am J Respir Cell Mol Biol. 2014;50:158–69. Highly relevant study demonstrating that inhibition of NOX4 activity employing a small molecule antagonist decreased TGF-β1-induced upregulation of profibrotic genes in normal human lung fibroblasts in vitro and attenuated established lung fibrosis in vivo in bleomycin-induced animal model of pulmonary fibrosis.PubMed
131.••
go back to reference Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014;6:231ra47. doi:10.1126/scitranslmed.3008182. This interesting study demonstrates that aged mice display persistent lung fibrosis following intratracheal bleomycin administration whereas young mice resolve the fibrotic process. The mechanisms involve NOX4/Nrf2 redox imbalance-induced fibroblast senescence coupled with apoptosis resistance causing a failure to resolve fibrosis.PubMed Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014;6:231ra47. doi:10.​1126/​scitranslmed.​3008182. This interesting study demonstrates that aged mice display persistent lung fibrosis following intratracheal bleomycin administration whereas young mice resolve the fibrotic process. The mechanisms involve NOX4/Nrf2 redox imbalance-induced fibroblast senescence coupled with apoptosis resistance causing a failure to resolve fibrosis.PubMed
Metadata
Title
Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis Pathogenesis
Authors
Sonsoles Piera-Velazquez
Sergio A. Jimenez
Publication date
01-01-2015
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 1/2015
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0473-0

Other articles of this Issue 1/2015

Current Rheumatology Reports 1/2015 Go to the issue

Antiphospholipid Syndrome (D Erkan, Section Editor)

Pulmonary Hypertension in Antiphospholipid Syndrome

Chronic Pain (R Staud, Section Editor)

Sleep Disturbance and Chronic Widespread Pain

Pediatric Rheumatology (S Ozen, Section Editor)

Biomarkers for Childhood-Onset Systemic Lupus Erythematosus

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine